# A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Source: https://onco.cc/trials/nct06055959/  
OnCo record `nct06055959` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Zilucoplan in childhood cancers, run by UCB Biopharma SRL, now recruiting.

## Summary

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06055959 by UCB Biopharma SRL, with 8 participants planned, started 2024-10-16 and due to reach its primary completion in 2026-11-16. Interventions recorded: Zilucoplan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06055959
- Phase: 2/3
- Setting: A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
- Sponsor: UCB Biopharma SRL
- Enrolled: 8

## Sources

- ClinicalTrials.gov NCT06055959: https://clinicaltrials.gov/study/NCT06055959

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [UCB](https://onco.cc/companies/ucb/)

---
JSON: https://onco.cc/api/v1/entities/nct06055959.json